Maternal colonization with Streptococcus agalactiae and associated stillbirth and neonatal disease in coastal Kenya by Greg, Fegan
 Cronfa -  Swansea University Open Access Repository
   
_____________________________________________________________
   
This is an author produced version of a paper published in :
Nature Microbiology
                                  
   
Cronfa URL for this paper:
http://cronfa.swan.ac.uk/Record/cronfa28304
_____________________________________________________________
 
Paper:
Seale, A., Koech, A., Sheppard, A., Barsosio, H., Langat, J., Anyango, E., Mwakio, S., Mwarumba, S., Morpeth, S.,
Anampiu, K., Vaughan, A., Giess, A., Mogeni, P., Walusuna, L., Mwangudzah, H., Mwanzui, D., Salim, M., Kemp, B.,
Jones, C., Mturi, N., Tsofa, B., Mumbo, E., Mulewa, D., Bandika, V., Soita, M., Owiti, M., Onzere, N., Walker, A.,
Schrag, S., Kennedy, S., Fegan, G., Crook, D. & Berkley, J. (2016).  Maternal colonization with Streptococcus
agalactiae and associated stillbirth and neonatal disease in coastal Kenya. Nature Microbiology, 1(7), 16067
http://dx.doi.org/10.1038/nmicrobiol.2016.67
 
 
 
 
 
 
 
 
_____________________________________________________________
  
This article is brought to you by Swansea University. Any person downloading material is agreeing to abide by the
terms of the repository licence. Authors are personally responsible for adhering to publisher restrictions or conditions.
When uploading content they are required to comply with their publisher agreement and the SHERPA RoMEO
database to judge whether or not it is copyright safe to add this version of the paper to this repository. 
http://www.swansea.ac.uk/iss/researchsupport/cronfa-support/ 
 1 
 
Maternal colonisation with Streptococcus agalactiae, and associated 1 
stillbirth and neonatal disease in coastal Kenya  2 
 3 
Anna C Seale (DPhil),
1,2*
 Angela C Koech (MBChB),
2
 Anna E Sheppard (PhD),
3
 Hellen C Barsosio (MBChB),
2
 4 
Joyce Langat (HND),
2
 Emily Anyango (HND),
2
 Stella Mwakio (HND),
2
 Salim Mwarumba (MSc),
2
 Susan C Morpeth 5 
(PhD),
2,4
 Kirimi Anampiu (HND),
2
 Alison Vaughan (BSc),
3
 Adam Giess (MSc),
3
 Polycarp Mogeni (MSc),
2
 Leahbell 6 
Walusuna (MSc),
2
 Hope Mwangudzah (HND),
2
 Doris Mwanzui (RN),
5
 Mariam Salim (RN),
2
 Bryn Kemp (DPhil),
2,6
 7 
Caroline Jones (PhD),
1,2,4
 Neema Mturi (MRCPCH),
2
 Benjamin Tsofa (DPH),
2
 Edward Mumbo (BScN),
7
 David 8 
Mulewa (MBChB),
7
 Victor Bandika (MMed),
8 
Musimbi Soita (MMed),
9
 Maureen Owiti (MMed),
6
 Norris Onzere 9 
(MMed),
5
 A Sarah Walker (PhD),
3
 Stephanie J Schrag (DPhil),
10
 Stephen H Kennedy (MD),
6
 Greg Fegan (PhD),
1,2
 10 
Derrick Crook W (FRCPath),
3
 James A Berkley (FRCPCH).
1,2 11 
 12 
1. Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, University of Oxford, 13 
UK. 14 
2. KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.  15 
3. Modernizing Medical Microbiology Consortium, Nuffield Department of Clinical Medicine, University of Oxford, 16 
UK. 17 
4. London School of Hygiene and Tropical Medicine, London, UK 18 
5. Maternity Department, Kilifi County Hospital, Kilifi, Kenya 19 
6. Nuffield Department of Obstetrics and Gynaecology, University of Oxford, UK.
 20 
7. County Ministry of Health, Kilifi, Kenya.
 21 
8. Department of Paediatrics, Coast Provincial General Hospital, Mombasa, Kenya.
 22 
9. Department of Obstetrics and Gynaecology, Coast Provincial General Hospital, Mombasa, Kenya. 
 23 
10. Division of Bacterial Diseases, Centers for Disease Control and Prevention, Atlanta, USA. 
 24 
 25 
Abstract 198/200 26 
Main Text 3496/3500  27 
2 
 
Abstract  28 
Streptococcus agalactiae (Group B Streptococcus, GBS) causes neonatal disease and stillbirth, 29 
but its burden in sub-Saharan Africa is uncertain. We assessed maternal recto-vaginal GBS 30 
colonisation (7967 women), stillbirth and neonatal disease. Whole genome sequencing was 31 
used to determine serotypes, sequence types (ST), and phylogeny. We found low maternal 32 
GBS colonisation prevalence (934/7967, 12%), but comparatively high incidence of GBS-33 
associated stillbirth and early onset neonatal disease (EOD) in hospital (0.91(0.25-2.3)/1000 34 
births; 0.76(0.25-1.77)/1000 live-births respectively). However, using a population denominator, 35 
EOD incidence was considerably reduced (0.13(0.07-0.21)/1000 live-births). Treated cases of 36 
EOD had very high case fatality (17/36, 47%), especially within 24 hours of birth, making under-37 
ascertainment of community-born cases highly likely, both here and in similar facility-based 38 
studies. Maternal GBS colonisation was less common in women with low socio-economic 39 
status, HIV infection and undernutrition, but when GBS-colonised, they were more likely 40 
colonised by the most virulent clone, CC17. CC17 accounted for 267/915(29%) of maternal 41 
colonising (265/267(99%) serotype III, 2/267(0.7%) serotype IV), and 51/73(70%) of neonatal 42 
disease cases (all serotype III). Trivalent (Ia/II/III) and pentavalent (Ia/Ib/II/III/V) vaccines would 43 
cover 71/73(97%) and 72/73(99%) of disease-causing serotypes respectively. Serotype IV 44 
should be considered for inclusion, with evidence of capsular switching in CC17 strains. 45 
  46 
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Introduction 47 
A half of all child deaths (<5 years) worldwide are in Sub-Saharan Africa (sSA),1 and a third of 48 
these deaths are in the neonatal period, from infection, preterm birth and neonatal 49 
encephalopathy.1 Stillbirths likely equal neonatal deaths in number, and infections are a major 50 
contributor.2 Streptococcus agalactiae (Group B Streptococcus, GBS) causes neonatal early 51 
and late onset disease (EOD, LOD), stillbirth,3 and possibly contributes to preterm birth4 and 52 
neonatal encephalopathy,5 from ascending maternal genito-urinary colonisation (Supplementary 53 
Table 1 gives definitions). Whilst GBS emerged as the leading cause of EOD in the United 54 
States in the 1960s6 and subsequently in Europe, in sSA, there remain major questions as to 55 
whether GBS commonly colonises pregnant women, causes stillbirth, or is an important cause 56 
of neonatal disease. Establishing this is essential, to inform potential preventive interventions. In 57 
resource-rich countries, reductions in EOD have followed the introduction of maternal 58 
microbiological or risk factor screening with intra-partum antibiotic prophylaxis (IAP).7 However, 59 
there is uncertainty as to the feasibility of this approach in resource-poor settings, and there is 60 
no evidence of effectiveness of IAP in preventing GBS-associated stillbirth, or LOD. Antisepsis 61 
at delivery has been shown to be ineffective.8 However, maternal vaccination may provide a 62 
feasible strategy to reduce GBS disease in resource-poor countries. A trivalent conjugate 63 
vaccine (serotypes Ia/Ib/III) has completed phase 2 clinical trials,9 and a pentavalent vaccine is 64 
in development.10 65 
Understanding which women are most likely to be GBS colonised could provide insight into both 66 
the emergence of GBS, and variation in reported prevalence of maternal GBS colonisation: 67 
Europe/United States 5-40%,11,12 Africa 9-47% (Supplementary Table 2). Reported maternal 68 
risk factors for colonisation are conflicting, with increased maternal GBS colonisation reported in 69 
both younger13 and older14 age groups; African-American mothers,13-15 and those with higher 70 
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education,14,16 higher income,16 high sexual activity,14 and obesity.15,16 Data from sSA are 71 
limited, but are also conflicting for potentially important risk factors such as HIV-infection. In 72 
South Africa, maternal GBS colonisation was lower in HIV-infected mothers17 but in Malawi, 73 
only amongst HIV-infected mothers with lower CD4 counts.18 In the USA15 and Zimbabwe19 no 74 
association with HIV was found. The limited data from studies in Kenya, Zimbabwe, Malawi and 75 
South Africa on colonising maternal serotypes in sub-Saharan Africa suggest serotype III is the 76 
most common (Ia/Ib/II/IV/V also reported).18,20-22 77 
For neonatal disease, data outside of the United States and Europe are sparse.23 In sSA, 78 
facility-based studies generally report a high incidence of neonatal GBS disease, but 79 
population-based and outpatient studies have reported much lower incidences,24,25 including 80 
what was described as a “striking absence” of invasive neonatal GBS disease in large out-81 
patient based studies.24 However, regional estimates, that included only four studies from Africa 82 
(one of which is our study site in Kilifi County)8,26-28 suggest that Africa may have the highest 83 
regional burden of neonatal GBS disease at 1.2(0.50-1.91)/1000 live-births.23 These limited data 84 
suggest that serotype III, as described in other regions,23 most commonly causes disease; for 85 
EOD and LOD in Malawi 52% and 72%;27 in South Africa 49% and 76%,29 with serotypes 86 
Ia/Ib/II/V also reported.27,29 The incidence of GBS-associated stillbirth is unknown in sub-87 
Saharan Africa,3 with data from two studies; one found no GBS-associated stillbirth,30 the other  88 
8/66(12%) stillbirths.31  89 
The population structure of GBS in Europe and the United States can be described by five 90 
major clonal complexes: CC1, CC10, CC17, CC19 and CC23,32,33 with CC17 overrepresented 91 
in disease isolates.32,34 These five clonal complexes are also found in Africa;32 in addition, CC26 92 
is common in some regions, representing 15% of sampled GBS isolates in Dakar and Bangui.35 93 
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GBS also causes bovine mastitis, which is largely mediated by the bovine-specific CC67, 94 
although the five major human clonal complexes can also be found in cattle.33,36,37 95 
In this study, we aimed to comprehensively describe the clinical epidemiology of maternal GBS 96 
colonisation, neonatal disease and stillbirth in coastal Kenya, with molecular analysis to 97 
determine associated serotypes, sequence types (ST), and phylogeny. 98 
 99 
Results  100 
Maternal GBS colonisation and adverse perinatal outcomes 101 
During the study, 10,130 pregnant women attended a health facility and we recruited 7,967 102 
(Figure 1, sample size Supplementary Table 3). Of these, 526/7967(6.6%) were from rural sites, 103 
5470/7967(68.7%) from semi-rural and 1971/7967(24.7%) from an urban site. There were some 104 
differences in demographics in those excluded (Supplementary Table 4), with emergency 105 
referrals more likely to be excluded as well as women with incomplete data on age, ethnicity or 106 
parity, although overall numbers were small. Transport times to the laboratory were longer from 107 
urban and rural sites (median 11h(range 0-48h); 11h(0-52h) respectively compared to semi-108 
rural (5h(0-73h)), but there was no evidence of association between GBS isolation and time to 109 
sample processing across all sites (OR=1.00(0.99-1.00) p=0.6)), across rural and urban sites 110 
(OR=0.99(0.98-1.00)), or each site individually (Supplementary Figure 1). 111 
Overall, 934 (11.7%(11.0-12.5%)) women were GBS-colonised at delivery. Prevalence was 112 
lowest at the rural sites (47/526, 8.9%(6.6-11.7%)), intermediate in the semi-rural site 113 
(608/5470, 11.1%(10.2-12.0%)) and highest at the urban site (279/1971, 14.2%(12.6-15.8%); 114 
trend P<0.001). However, after adjustment for other risk factors (including maternal age, socio-115 
economic status and ethnicity; univariable analyses Supplementary Table 5), the odds of 116 
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isolating GBS at the urban site (OR=0.95(0.92-0.98)) and rural site (OR=0.91(0.88-0.94)) were 117 
lower than at the semi-rural site (p<0.001), Table 1.  118 
GBS colonisation was independently associated with maternal age, highest in the middle 119 
categories (Supplementary Figure 2; p=0.023), and parity (>5 vs 1-4) (OR=0.81(0.70-0.93) 120 
p<0.001) as well as Mijikenda ethnicity (indigenous population, OR=0.73(0.59-0.90) p=0.003) 121 
(Table 1). GBS colonisation was increased in women with higher socio-economic status 122 
(OR=1.21(1.13-1.29), p<0.001) and those who had contact with cattle (OR=1.29(1.17-1.43) 123 
p<0.001). GBS colonisation was reduced amongst HIV-infected women, and especially in HIV-124 
infected women taking co-trimoxazole prophylaxis (OR=0.68(0.42-1.09); OR=0.24(0.14-0.39), 125 
p<0.001), in less well-nourished mothers (OR=0.72(0.60-0.88), p<0.001) and women with 126 
obstetric emergencies (OR=0.85(0.79-0.92), p<0.001). 127 
There was evidence that adverse perinatal outcomes (very preterm delivery, very low birth-128 
weight, stillbirth, possible serious bacterial infection (definitions Supplementary Table 1) were 129 
associated with maternal GBS colonisation in multivariable models in the context of interactions 130 
with clinical risk factors for invasive GBS disease, such as maternal temperature >37.5°C, 131 
urinary tract infection, and prolonged rupture of membranes >18h (Figure 2, Supplementary 132 
Tables 6-9). In contrast, without GBS colonisation there was no evidence that these clinical 133 
factors conferred elevated risk of poor outcomes. There was no evidence of association of 134 
maternal GBS colonisation with perinatal mortality (p=0.7; Supplementary Table 10), including 135 
testing for an interaction with any risk factor for GBS disease (p=0.4). 136 
Of 918/934(98.3%) colonising isolates available and extracted, 915/934(98.0%) were of 137 
sufficient quality for genomic analysis. Amongst colonised mothers, 658/915(71.9%) of GBS 138 
isolates were serotypes Ia, Ib or III; serotype III being most common (350/915(38.3%)); Clonal-139 
complex 17 (CC17) comprised 267/915(29.2%), Figures 3 and 4, Supplementary Table 11, 140 
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GBS- colonised women. Of these, 265/267(99.3%) were serotype III and 2/267(0.7%) were 141 
serotype IV.  142 
The population structure was broadly similar to other parts of the world, with 114/915(12.5%) 143 
CC1, 148/915(16.2%) CC10, 268/915(29.3%) CC17, 173/915(18.9%) CC19, 208/915(22.7%) 144 
CC23, whilst 4/915(0.4%) did not belong to any commonly described clonal complex. No 145 
bovine-associated CC-6738 GBS isolates were identified. Each of the five major clonal 146 
complexes were represented at each site (Figure 4, Supplementary Table 12), with no evidence 147 
for geographic stratification. Within clonal complexes, there was considerable diversity, with a 148 
total of 43 distinct STs, 18 of which were newly identified in this study. The largest number of 149 
STs was seen in CC17 (12 STs total, 8 newly identified). The most common STs within CC17 150 
were ST17 (183/268,68.3%) and ST484 (67/268,25.0%).  151 
Within GBS-colonised women, risk factors for colonisation with the most virulent clone CC17, 152 
were, in general, the reverse of those associated with GBS colonisation overall (Table 2). 153 
Maternal GBS CC17 was increased in the rural site (OR=1.26(1.20-1.31), p<0.001), women of 154 
Mijikenda ethnicity (OR=1.62(1.43-1.85), p<0.001), and women with HIV-infection and women 155 
with HIV-infection taking co-trimoxazole (OR=1.46(1.11-1.92); OR=4.30(0.59-31.3), p<0.001). 156 
Mothers who had cattle contact (OR=0.54(0.45-0.64), p<0.001) and were better nourished 157 
(OR=0.79(0.42-1.49), p<0.001) were less frequently colonised with CC17, but this did not hold 158 
for ST-17 (Supplementary Table 13). For each of the risk factors, including cattle contact, the 159 
corresponding isolates were dispersed in the phylogeny (Figure 4), suggesting that the 160 
associations were not driven by specific sub-lineages.  161 
Pairwise comparison of all maternal colonising isolates in mothers delivering at Kilifi County 162 
Hospital showed increased genetic similarity in a small number of mothers who delivered within 163 
7 days of each other, but not according to household location (Supplementary Figure 3). Of 164 
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mothers admitted <7 days apart, in Kilifi County Hospital, there were 14/91013(1.4%) pairs from 165 
mothers admitted on the same day with 0-4 Single Nucleotide Variant (SNV) differences, 166 
11/1967(0.6%) 1 day apart, 2/1845(0.1%) 2 days apart and 2/1832(0.1%) 6 days apart 167 
(p<0.001). At the rural sites, of mothers admitted <7 days apart, there were 2/124(1.6%) pairs 168 
from mothers admitted on the same day with 0-4 SNV differences and 2/219(0.9%) 1 day apart 169 
(p=0.1). At the urban site, there were 8/987(0.8%) pairs from mothers admitted on the same day 170 
with 0-4 SNV differences and 3/1555(0.2%) 1 day apart (p<0.001).22 171 
GBS in mother-neonatal pairs (surface contamination) 172 
We recruited 830 mother and baby pairs at KCH (Figure 1, and Supplementary Table 14); 173 
104/830 (12.5%(10.4-15.0%)) mothers were colonised with GBS at delivery and 44/830 174 
(5.3%(3.9-7.1%)) neonates had GBS isolated from ear, umbilicus or nose within 6h of delivery. 175 
30/44(68.2%) neonates with surface GBS were born to one of the 104 GBS-colonised mothers 176 
and 14/44(31.8%) were born to one of the 726 mothers without colonising GBS detected; of 177 
which 2/14(14.3%) were born by caesarean section. Odds of neonatal surface GBS were high 178 
with maternal GBS colonisation (OR=20.6(10.5-40.6,p<0.001)).  179 
Pairwise SNV comparisons between maternal and newborn isolates showed a clear bimodal 180 
distribution: 26/30(86.7%) pairs differed by ≤4 SNVs (all pairs the same ST and serotype), 181 
presumably representing vertical transmission, and 4/30(13.3%) pairs were highly divergent 182 
(>9000 SNVs, with different STs and different serotypes), Figure 4. Combining all pairs with ≤4 183 
SNVs, the SNVs were dispersed throughout the genome, with no gene represented more than 184 
once. There were 7/44(15.9%) neonates with surface GBS after delivery by caesarean section, 185 
5 of their mothers had GBS detected; 3/5 had 0 SNV differences, 1/5 1 SNV, and 1/5 9673 186 
SNVs. 187 
 188 
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Stillbirth 189 
There were 278 stillbirths during the nested case-control study (278/4394(6.3%) all births). We 190 
sampled cord blood in 149/278(53.6%) (94/149(63.1%) intra-partum, 55/149 (36.9%) ante-191 
partum stillbirths) 104 also had a lung aspirate; 34/278 (12.2%) had a lung aspirate sample only. 192 
In total 183/278(65.8%) stillbirths were sampled, plus 330 live-birth cord blood controls (Figure 193 
1).  194 
GBS was isolated from 4/183 (2.2%(95%CI0.6-5.5)) stillbirths (3/149 cord blood samples, 2/138 195 
lung aspirates; one stillbirth had GBS isolated from both); two ante-partum (36 and 39 weeks’ 196 
gestation) and two intra-partum (35 and 39 weeks’). Overall minimum incidence of GBS-197 
associated stillbirth (cord blood or lung aspirate) was 0.91(0.3-2.3)/1000 births. Compared to 198 
live-born controls (GBS isolated from 1/330(0.3%)), GBS was isolated more frequently from 199 
cord-blood in stillbirths (OR=6.8(0.7-65.5), p=0.09), and in a multinomial model ante-partum 200 
stillbirths (OR=12.4(1.1-139.3)) and intra-partum stillbirth (OR=3.5(0.2-57.1) exact p=0.055). 201 
Serotype data were available from three stillbirths; two were serotype V and one serotype III. 202 
There were 2/4 GBS-associated stillbirths born to GBS colonised mothers (2/2 pairs differed by 203 
0 SNVs, all ST1, serotype V); one mother was not colonised, one was not tested. Risk ratio for 204 
GBS-associated stillbirth in GBS-colonised vs non-colonised mothers 7.6(1.1-52.6, p=0.016).  205 
Neonatal disease 206 
Eighty-two neonates with invasive GBS disease were admitted to KCH (1998-2013, Figure 1): 207 
36/82(43.9%) and 43/82(52.4%) with EOD and LOD respectively (3 unknown). Case fatality was 208 
highest in EOD 17/36(47.2%) despite treatment, particularly for those diagnosed <24h of birth 209 
(11/18(61.1%)). In cases of LOD, 5/43(11.6%) died. Most GBS EOD cases (52/82(63.4%)) were 210 
male, and 25/82(30.5%) were <2500g at admission (Supplementary Table 15). Sepsis without 211 
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focus was predominant in EOD (33/36(91.6%)), with meningitis (+/- sepsis) being more common 212 
in LOD (21/43(48.8%)), (Figure 3). Gestational age was not routinely available from prior clinical 213 
surveillance data, however, there were five EOD cases with gestations of 36, 36, 37, 37 and 40 214 
weeks’ born at the time of the prospective cohort study (vs median 38 (IQR 36-40) overall in 215 
prospective cohort).  216 
EOD incidence amongst deliveries at KCH during the cohort study (2011-13) was 0.76(0.25-217 
1.77)/1000 live-births. Including only residents in KHDSS population (1998-2013), the 218 
(minimum) population-based incidence of neonatal GBS disease was 0.34(0.24-0.46)/1000 live-219 
births: EOD 0.13(0.07-0.21)/1000 live-births and LOD 0.21(0.14-0.31)/1000 live-births; with no 220 
evidence of a trend over the study period (Supplementary Figure 4).  221 
There were 73/82(89.0%) neonates with invasive isolates available and extracted, and all were 222 
of sufficient quality for inclusion in the final analysis. Serotypes Ia/Ib/III caused 71/73(97.3%) 223 
and serotypes Ia/Ib/II/III, caused 72/73(98.6%) of EOD and LOD. Serotype III predominated in 224 
both EOD (18/30(60.0%)) and LOD (36/40(90.0%); p=0.003 χ2test for trend); these isolates 225 
were all CC17, except 1 CC-19 isolate (Figure 4). Serotype III was the almost universal cause of 226 
meningitis; 22/23(95.7%) cases, of which 21/22(95.4%) were CC17; Figure 3, Supplementary 227 
Table 16. Isolates were all susceptible to penicillin and 61/76(80.3%) were susceptible to co-228 
trimoxazole.  229 
Three of the five neonates with EOD born at KCH (2011-2013) were born to GBS-colonised 230 
mothers (1/3 pairs differed by 0 SNVs (both ST17, serotype III), 1/3 88 SNVs (1 ST17, 1 ST484, 231 
both serotype III) and 1/3 1002 SNVs (both ST17, serotype III): risk ratio (RR) for EOD for GBS-232 
colonised vs non-colonised mothers 11.8(2.0–70.3) p<0.001. For all perinatal GBS disease 233 
(EOD or stillbirth) RR=13.1(3.1–54.8, p<0.001). 234 
11 
 
 235 
Discussion 236 
GBS is an important cause of stillbirth and neonatal disease in Kenya. The incidence of stillbirth 237 
was comparable to early onset disease (EOD) in hospital births ((0.91(0.25-2.3)/1000 births) 238 
and 0.76(0.25-1.77)/1000 live-births respectively). These incidences are all underestimates, with 239 
samples not taken from all stillbirths, and insensitivity in cultures, particularly if intrapartum 240 
antibiotics were given. The much lower population-based incidence of EOD (0.13(0.07-241 
0.21)/1000 live-births) suggests recruitment bias with under ascertainment of cases in the 242 
community, or in out-patient settings, due to rapid case fatality after delivery and limited access 243 
to care. This is supported by the higher proportion of late onset disease (LOD), which is the 244 
reverse of the ratio of GBS disease typically seen in high-income countries.23 Whilst it could be 245 
argued that facility delivery is a risk factor for EOD (if there was in-hospital maternal GBS 246 
acquisition), we found very limited evidence of horizontal transmission in facilities, with few 247 
genetically near-identical pairs (0-4 SNVs, threshold determined empirically from newborn 248 
surface contamination study) in mothers admitted <7days of each other. 249 
However, there may be true differences in incidence of both GBS-associated stillbirth and 250 
neonatal GBS disease in sub-Saharan Africa, neither explained by study design nor other 251 
methodological limitations. The incidences of neonatal GBS disease recently reported in urban 252 
South Africa29 and Malawi23 are high, and could be due to differences in maternal GBS 253 
colonisation prevalence; consistent with our finding of higher prevalence of maternal GBS 254 
colonisation in urban compared to semi-rural and rural residents. This association was 255 
explained by variables describing improved socio-economic status, and other factors associated 256 
with improved health, such as better nutritional status, being in the middle age categories, and 257 
lower parity, both in the complete-case analyses and using multiple imputation. Whilst our study 258 
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includes impoverished populations, the pattern of risk factors identified is consistent with recent 259 
studies in high-income countries reporting increased maternal GBS colonisation with higher 260 
education14,16 and higher income.16 The reasons for this are unclear, but it likely relates to 261 
changes in the maternal microbiome, with different community-states reported.39 262 
Use of prophylactic co-trimoxazole amongst HIV-infected women had a clear negative 263 
association with GBS colonisation. Previously reported conflicting findings,17,18 may depend on 264 
the frequency of antimicrobial use (and provision of anti-retroviral therapy). In contrast, neonatal 265 
GBS disease is increased with HIV-exposure,40 with reduced maternal GBS capsular antibody 266 
in HIV-1 infection,41,42  and/or because, as shown here, the most virulent clone, CC17, is more 267 
frequently found in HIV-infected GBS colonised women, compared to other non-CC17 types. 268 
There have been a number of virulence factors (adhesins, invasins and immune evasins) 269 
associated with increased ability of GBS to colonise and cause disease,43 with the more 270 
homogeneous CC17 having acquired its own set of virulence genes,38 and increased ability to 271 
form biofilms in acidic conditions.44 272 
We observed an association between cattle contact and maternal GBS colonisation, however, 273 
no bovine-associated CC-67 isolates were identified, and the isolates from women with cattle 274 
contact were from a variety of lineages representing all major CCs. Little is known about bovine 275 
GBS populations in Kenya, and it is possible that the human and bovine populations are similar, 276 
and thus the association between cattle contact and maternal GBS colonisation from genuine 277 
transmission, as suggested elsewhere.45 Alternatively, women who look after cattle may be of 278 
higher socio-economic status and thus the association due to residual confounding. 279 
The overall GBS population structure here is similar to previous studies from a variety of 280 
geographic locations, supporting the notion of recent global dissemination of relatively few 281 
clones.32 Within this study, we found no evidence for geographic clustering of related isolates, 282 
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both at the level of sampling location (Figure 4), as well as distance between households 283 
(Supplementary Figure 3), further suggesting rapid geographic dispersal of GBS. However, in 284 
contrast to a previous study from Africa,35 we found no CC-26 isolates, suggesting this lineage 285 
may be geographically restricted. Furthermore, we found a large number of ST-484 isolates 286 
67/915(7.3%) of total, 67/268(25.0%) of CC17; this lineage has previously been reported in only 287 
a single study, also from Kenya.46 We also identified three novel STs that represent single-locus 288 
variants of ST-484. Taken together, it is possible that ST-484 originated in or near Kenya, with 289 
relatively little geographic dispersal. Alternatively, there may be a lack of GBS sampling in other 290 
locations where ST-484 is present. 291 
Prevention strategies in resource-rich settings focus on reducing EOD through intra-partum 292 
antibiotic prophylaxis (IAP) using either microbiological or risk-factor screening to identify at-risk 293 
mothers;7 both strategies would be challenging in resource-poor settings. Of interest, when 294 
comparing these strategies, however, is the fact that associations with adverse perinatal 295 
outcomes were only detected through interactions between maternal GBS colonisation and 296 
clinical risk factors. This supports a mechanism of action whereby colonising maternal GBS 297 
ascends, leading to chorioamnionitis (intra-amniotic infection) and fever in a small proportion of 298 
women, leading to poor perinatal outcomes. Neither maternal GBS colonisation without signs of 299 
infection, nor maternal fever without GBS colonisation increased the risk of adverse perinatal 300 
outcomes. Thus either approach (microbiological or risk-factor screening) will target far larger 301 
numbers than those actually at risk. Any direct association between maternal GBS colonisation 302 
and adverse outcomes may also be diluted by the many other causes of adverse perinatal 303 
outcomes, and by misclassification (e.g. uncertainty over the date of the last menstrual period to 304 
determine gestation), which may explain some of the conflicts in findings in studies assessing 305 
the contribution of GBS to preterm birth.4  306 
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We demonstrated vertical transmission of maternal GBS colonisation in maternal-newborn 307 
dyads, for both surface contamination (including in cases of emergency caesarean section) and 308 
perinatal disease. Genetically divergent maternal-newborn dyads may reflect un-sampled 309 
variation in the mother, as only a single colony was sequenced in each case. Whilst adaptive 310 
mutations associated with disease progression have been reported elsewhere from the 311 
comparison of mother-newborn pairs,47 we were unable to find evidence for this in the current 312 
study, as all pairs involving invasive isolates were either genetically identical (0 SNVs), or 313 
divergent enough to argue against this. The findings show GBS infection occurs prior to 314 
delivery; supporting the need for IAP to be administered before delivery to be effective, and 315 
showing why antisepsis in active labour, for example vaginal chlorhexidine wipes, are ineffective 316 
in reducing neonatal EOD.8 The finding of 14/44(31.8%) newborns with surface GBS 317 
contamination, where maternal GBS colonisation was not identified suggests insensitivity of 318 
maternal recto-vaginal screening, despite the consistent use of broth-enrichment and blood agar 319 
to maximise sensitivity. This is a higher percentage than a recent study in The Gambia 320 
(40/186(21.5%)),48 but this study excluded mothers at high risk for pregnancy complications. 321 
Similarly to repeat vaginal examinations, as seen here and reported elsewhere,49 complicated 322 
deliveries (obstetric emergencies) likely decrease GBS sampling sensitivity, through antisepsis 323 
measures, or mechanical removal.  324 
With limitations in the clinical benefit of IAP in terms of reducing stillbirth and LOD, as well as 325 
challenges in effective implementation to reduce EOD in sSA, maternal vaccination is an 326 
attractive strategy for prevention. The most advanced vaccine (completed phase 2 trials) is 327 
trivalent (Ia/Ib/III), but plans are to advance a pentavalent vaccine.10 If this includes the most 328 
common disease-causing serotypes worldwide (Ia/Ib/II/III/V), it will cover almost all 329 
72/73(98.7%) of the serotypes causing invasive disease in this study. However, importantly for 330 
vaccine development, and in line with other reports,50 we identified capsular switching to 331 
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serotype IV in 2 isolates within CC17, suggesting consideration of inclusion of serotype IV is 332 
warranted. 333 
GBS is an important, potentially preventable, cause of stillbirth and neonatal death in coastal 334 
Kenya. Maternal GBS colonisation is increased with urbanisation and higher socio-economic 335 
status, and likely to increase with development. GBS neonatal disease in population-based 336 
studies is markedly under-ascertained through rapid case fatality after birth and limited access 337 
to care, and is equalled by the burden of GBS-associated stillbirth. Maternal GBS vaccination is 338 
a key opportunity to reduce stillbirth and neonatal death in this high burden region. 339 
 340 
Methods 341 
Study design 342 
The study design included a prospective cohort at rural, semi-rural and urban sites, a nested 343 
case-control study in the semi-rural site, and analysis of surveillance of neonatal disease at the 344 
semi-rural site (Figure 1). 345 
Prospective cohort study: In a prospective cohort study (2011-13), we assessed prevalence and 346 
risk factors for maternal GBS colonisation at delivery, and perinatal outcomes at delivery 347 
(stillbirth, gestational age, birth-weight, possible serious bacterial infection, and perinatal death).  348 
Nested case control study: Investigation of stillbirth was undertaken with a nested case-control 349 
study; Cord blood cultures were taken at delivery from the stillbirth, and the next two 350 
subsequent admissions that were live-born (case: controls 1:2). Lung aspirates were taken from 351 
stillbirths only, by a study clinician attending within 4 hours of the stillbirth. 352 
Surveillance of neonatal invasive bacterial disease: Neonatal disease was quantified using 353 
systematic clinical and microbiological surveillance data (1998-2013 at Kilifi County Hospital) 354 
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within the Kilifi Health and Demographic Surveillance System (KHDSS) area, giving accurate 355 
population and birth denominators (see study sites).51  356 
Study sites 357 
The studies were conducted at Coast Provincial General Hospital, Mombasa (CPGH) (urban, 358 
~12,000 deliveries/year, comprehensive obstetric care); Kilifi County Hospital (KCH) (semi-rural, 359 
~3000 deliveries/year, comprehensive obstetric care); Bamba sub-district hospital (rural, ~600 360 
deliveries a year, basic obstetric care) and Ganze health facility (rural, ~400 deliveries a year, 361 
basic obstetric care). 362 
A part of Kilifi County is included in detailed health and demographic surveillance (KHDSS)51 363 
from which accurate population data are available from 2004. Kilifi County Hospital (KCH) is the 364 
main district hospital which serves this population, so incidence estimates for residents seeking 365 
health care at KCH can be made with the KHDSS population as the denominator. We used 366 
prospectively collected data on live births from the regular re-enumerations of the KHDSS 367 
population, and used the estimated slope from a regression to estimate the number of births 368 
prior to the start of KHDSS. 369 
Study population 370 
Prospective cohort study: We included all women admitted for delivery at study sites admitted at 371 
designated times who gave written informed consent, without additional exclusion criteria. We 372 
planned to recruit over one calendar year (to allow for seasonality), but extended enrolment to 373 
meet sample size requirements (Supplementary Table 3) because national strikes closed 374 
government health facilities twice during the study. Recruitment was done at CPGH for 48 hours 375 
each week (01.04.2012-31.07.2013), at Bamba and Ganze for 6 days each week (01.07.2012-376 
31.07.2013) and at KCH every day (01.08.2011-31.07.2013) including additional studies of 377 
neonatal surface contamination (01.05.2012 to 31.07.2013) 378 
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Nested case control study: We included all stillbirths delivered in Kilifi County Hospital and the 379 
next two consecutive live births (01.05.2012-01.10.2013). 380 
Surveillance of neonatal invasive bacterial disease: We included all neonates admitted to Kilifi 381 
County Hospital (01.08.1998-1.10.2013). 382 
Sampling and laboratory methods 383 
Prospective cohort study: We took recto-vaginal swabs during routine vaginal examination at 384 
admission for delivery, when possible prior to rupture of membranes. A small cotton swab was 385 
used to wipe the lower third of the vaginal mucosa and then the inside surface mucosa of the 386 
anus,52 according to standard procedures. Neonatal surface swabs (to assess surface 387 
contamination) included the external ear, nares and umbilicus. Swabs were placed into Amies 388 
transport medium with charcoal,53 refrigerated, transported in cool containers53 to the research 389 
laboratory (participating in UK National External Quality Assessment Service) and processed by 390 
standard protocols (including enrichment (LIM broth) and sub-culture onto blood agar). Isolates 391 
with GBS morphology were CAMP tested and definitive grouping done using a Streptococcal 392 
grouping latex agglutination kit (PRO-LAB Diagnostics, USA).  393 
Nested case control study: For stillbirths and live-born controls, we sampled cord blood at 394 
delivery after double clamping the cord if necessary and cleaning with 70% ethanol. We 395 
processed cord blood cultures using an automated culture system (BACTEC 9050, Becton 396 
Dickinson, UK). We took lung aspirate samples (stillbirths only) with a sterile technique 397 
aspirating the lung, within four hours of delivery. We examined lung aspirates with microscopy 398 
and culture using standard methods within 30 minutes of sampling, or if delay was unavoidable 399 
stored at 2-8oC for up to 8 hours.  400 
Surveillance of neonatal invasive bacterial disease: For all neonatal admissions (1998-2013) at 401 
KCH, we sampled peripheral blood on admission for culture, prior to neonatal antibiotic 402 
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treatment (during 2011-2013, peri-partum maternal antibiotics were documented in 403 
36/5430(0.7%) of deliveries in KCH); we did lumbar puncture when clinically indicated. We 404 
tested isolates for antimicrobial susceptibility to penicillin and co-trimoxazole (British Society for 405 
Antimicrobial Chemotherapy). We processed blood cultures using an automated culture system 406 
(BACTEC 9050); we tested cerebrospinal fluid as described elsewhere.26  407 
Molecular methods 408 
We performed DNA extraction, Illumina sequencing (Hiseq technology) and raw read 409 
processing using standard methods starting from a single GBS colony. GBS isolates were 410 
frozen in 1mL vials and stored at -80°C prior to sub-culture on a Columbia blood agar plate for 411 
24-48 hours, followed by DNA extraction using a commercial kit (QuickGene, Fujifilm, Tokyo, 412 
Japan) from a single colony.  High throughput sequencing was undertaken at the Wellcome 413 
Trust Centre for Human Genetics (Oxford University, UK) using HiSeq2500, generating 150 414 
base paired-end reads. De novo assembly, mapping and variant calling were performed as 415 
previously described,54 except that mapping was to the S. agalactiae reference genome 416 
2603V/R (NC_004116.1). Sequence quality was assessed using various metrics (% reads 417 
mapped to reference genome, % reference positions called, contig number, total contig length). 418 
Sequence data showing poor quality metrics was excluded from further analysis; where 419 
practicable the corresponding samples were re-isolated, re-grouped and re-sequenced (if re-420 
grouping confirmed the isolate as GBS). Sequence data were submitted to the NCBI 421 
Sequence Read Archive under BioProject PRJNA315969. Individual accession numbers are 422 
provided in Supplementary Table 17 (BioProject PRJNA315969). 423 
We allocated serotype on the basis of BLASTn comparisons assessing sequence similarity of 424 
de novo assemblies with the capsular locus regions of each of the ten known GBS serotypes. 425 
We validated this method internally (kappa=0.92).55 Sequence types (ST) were also assigned in 426 
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silico using BLASTn with de novo assemblies. Novel STs were submitted to pubmlst.org for 427 
assignment.  Phylogenetic analysis was performed separately for each clonal complex using 428 
RAxML version 8.1.16, with an alignment consisting of all variable sites from mapping to the 429 
2603V/R reference, padded to the length of the reference with invariant sites of the same GC 430 
content as the original data. Recombination was detected using ClonalFrameML,56 and we 431 
present the resultant phylogenies with recombinant regions removed. To partition the isolates 432 
according to previously described clonal complexes, we first reconstructed a single RAxML 433 
phylogeny with all isolates. The resulting tree was then visually partitioned on long, deep 434 
branches, which effectively corresponded to previously described clonal complexes, but 435 
enabled us to include all STs. We have therefore used this partitioning as our definition of the 436 
clonal complexes. Using this definition, each ST belongs to a single clonal complex and each 437 
clonal complex is monophyletic (Supplementary Figure 6), indicating that partitioning by clonal 438 
complex remains appropriate when whole-genome data is taken into account. 439 
Pairwise comparison of SNV differences from mapped data was used to examine maternal and 440 
newborn paired GBS isolates, and possible transmission of GBS between mothers was 441 
investigated through these differences and epidemiological links in time and place (through 442 
delivery in Kilifi County Hospital) or residence (distance between household locations in Kilifi 443 
HDSS). 444 
Statistical analysis 445 
We used Stata (version 13.1) for statistical analyses. We used the first principal component 446 
from a set of household assets as a proxy for socio-economic status (SES).57 We used multiple 447 
imputation with chained equations (Stata mi) to impute missing data on potential risk factors 448 
(<15% per variable; 50 imputations). Continuous variables were checked for normality and 449 
transformation was not required. We used natural cubic splines to allow for non-linearity in 450 
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variable effects in imputation models. Imputations were done separately by maternal GBS 451 
status so that interactions could be examined in the analyses of adverse newborn outcomes. 452 
The same imputation was used for both analyses; by imputing separately for GBS colonisation 453 
there are fewer assumptions than if it was fitted as a covariate (allows variances of continuous 454 
imputed variables to differ according to GBS colonisation, and the associations between two 455 
imputed variables can be stronger in one group). 456 
We built multivariable logistic regression models using complete-case and imputed datasets 457 
(combined using Rubin’s rules) to examine risk factors for maternal GBS colonisation using 458 
robust variances reflecting clustering by site. We included non-linearity in continuous variables 459 
via natural cubic splines, with factors categorised at quartiles for presentation of final models. 460 
Risk factors with p<0.1 in univariable models were included in a multivariable model and final 461 
independent predictors identified using backwards elimination (exit p>0.1). We assessed 462 
whether risk factors for maternal GBS colonisation were associated with ST-17 (and CC17) 463 
colonisation in mothers who were GBS colonised using the same process, for complete-cases 464 
only. 465 
We used the imputed dataset in multivariable regression analyses to examine whether maternal 466 
GBS colonisation was associated with gestational length, birth-weight, possible serious bacterial 467 
infection, stillbirth or perinatal mortality. We included pre-specified confounders (age, parity, sex 468 
(of new-born), maternal education, SES, nutritional status, HIV status, obstetric complication 469 
and multiple delivery) and tested for interaction with GBS colonisation from prolonged rupture of 470 
membranes (PROM, >18h), maternal fever (>37.5°C) or urinary tract infection (leukocytes and 471 
nitrites present). We included these terms in multivariable models if there was evidence of 472 
interaction at the p<0.1 level. 473 
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We estimated the odds of isolating GBS from cord blood in all stillbirths, then ante-partum and 474 
intra-partum stillbirths, compared to live-births. We estimated incidence of GBS-associated 475 
stillbirth and neonatal disease using denominators of facility births, and community births, for 476 
residents of Kilifi Health and Demographic Surveillance Study.51 477 
 478 
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Table 1: Exposures associated with maternal Group B Streptococcus (GBS) colonisation  
   No GBSc GBSc   Complete cases (N=3979) Imputed data (N=7967) 
Variable  N not 
missing 
N not 
missing 
(%) 
OR 95%CI
a 
p
b
 OR 95%C
a 
p
b
 
Site Rural 479 47 (8.9) 0.80 (0.73-0.88) <0.001 0.91 (0.88-0.94) <0.001 
Semi-rural 4862 608 (11.1) 1  1  
Urban 1692 279 (14.2) 0.96 (0.93-1.00) 0.95 (0.92-0.98) 
Age in 
quartiles 
(years)
e 
 
<21.5 1674 166 (9.0 ) 0.77 (0.55-1.15) 0.009 0.80 (0.57-1.15) 0.023 
21.5-25.3 1663 223 (11.8) 1.15 (0.87-1.22) 1.03 (0.88-1.22) 
25.4-29.9 1656 213 (11.4) 1  1  
>30 1672 186 (10.0) 0.91 (0.78-1.18) 0.96 (0.79-1.18) 
Parity 0 2986 365 (10.9) 1.06 (0.99-1.09) <0.001 1.05 (1.00-1.10) <0.001 
1-4 3550 442 (11.1) 1  1  
>5 1341 119 (8.2) 0.85 (0.69-0.92) 0.81 (0.70-0.93) 
Ethnicity: No 2226 345 (13.4) 1  0.002 1  0.003 
Mijikenda
d
 Yes 5617 578 (9.3) 0.65 (0.60-0.90) 0.73 (0.59-0.90) 
Household 
socioeconomic 
status 
(quartiles)
e 
Very low 1086 96 (8.1) 0.88 (0.66-1.16) <0.001 0.89 (0.66-1.19) <0.001 
Low 2720 294 (9.8) 1  1  
Medium 2123 229 (9.7) 1.00 (0.82-0.92) 0.88 (0.82-0.93) 
High 2038 315 (13.4) 1.24 (1.06-1.30) 1.21 (1.13-1.29) 
Mother looks 
after cattle 
No 7471 873 (10.5) 1  <0.001 1  <0.001 
Yes 449 56 (11.1) 1.46 (1.17-1.42) 1.29 (1.17-1.43) 
Nutritional 
status (mid-
upper arm 
circumference 
in cm
e
) 
<23.9 1428 125 (8.0) 0.77 (0.60-0.89) <0.001 0.72 (0.60-0.88) <0.001 
24-25.9 2219 264 (10.6) 1  1  
26-27.9 1662 183 (9.9) 0.80 (0.66-1.07) 0.85 (0.67-1.08) 
>28 
2170 309 (12.5) 
1.02 (0.78-1.40) 1.05 (0.79-1.42) 
HIV infection 
 
No 7285 879 (10.8) 1    <0.001 1   <0.001 
Yes, no CTXf 239 20 (7.7) 1.16 (0.92-1.45) 0.68 (0.42-1.09) 
Yes, on CTXf
 
161 5 (3.0) 0.20 (0.14-0.26) 0.24 (0.14-0.39) 
Vaginal 
examination 
before swab 
No 4952 609 (11.0) 1    0.019 1    0.057 
Yes 
780 73 (8.6) 
0.57 (0.36-0.91) 0.83 (0.70-1.00) 
Obstetric 
complication 
No 6913 823 (10.6) 1  <0.001 1  <0.001 
Yes 1054 111 (9.5) 0.78 (0.70-0.88) 0.85 (0.79-0.92) 
a 
95% confidence intervals are given, based on robust standard errors to account for intracluster correlation within 
recruitment sites  
b 
p values
 
are derived from the Wald test (imputations combined using Rubin’s rules) 
c 
Full details on all variables and numbers for missing variables are given in Supplementary Table 4 
d 
Mijikenda are the indigenous coastal population 
e
 For continuous variables we tested for associations prior to categorisation and inclusion in the model. Where there was 
non-linearity, natural cubic splines were used (Supplementary Figure 2). Data were categorised for ease of presentation, and 
the largest group was used as the reference group.  
f
CTX=co-trimoxazole prophylaxis 
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Table 2: Exposures associated with maternal Group B Streptococcus (GBS) colonisation with clonal complex 17 
    GBS   
Univariable complete cases 
(N=914) 
Multivariable complete cases 
(N=728) 
Variable   Not CC17 N CC17 (%) OR 95%CI
a
 p
b
 OR 95%CI
a
 p
b
 
Site 
Rural 33 13 28.3 0.85 (0.43-1.65) 
0.072 
1.26 (1.20-1.31) 
<0.001 Semi-rural 403 187 31.7 1   1   
Urban 211 67 24.1 0.68 (0.49-0.95) 0.98 (0.79-1.04) 
Age in 
quartiles 
(years)
d
 
<21.5 115 49 29.9 1.16 (1.07-1.27) 
0.2 
1.21 (0.88-1.67) 
0.004 
21.5-25.3 156 60 27.8 1.05 (0.92-1.21) 0.88 (0.77-1.01) 
25.4-29.9 153 56 26.8 1   1   
>30 130 51 28.2 1.07 (0.85-1.35) 1.06 (0.74-1.51) 
Parity 
0 257 98 27.6 0.86 (0.49-1.51) 
0.4 
0.75 (0.35-1.55) 
<0.001 1 to 5 301 133 30.6 1   1   
>5 83 35 29.7 0.95 (0.83-1.10) 0.68 (0.60-0.80) 
Ethnicity: No 262 79 23.2 1   
<0.001 
1   
<0.001 
Mijikendac Yes 379 183 32.6 1.60 (1.52-1.69) 1.62 (1.43-1.85) 
Household 
socioeconomic 
status d 
(quartiles) 
Very low 71 25 26.0 0.61 (0.48-0.80) 
<0.001 
  
 
Low 192 95 33.1 1   
 
  
Medium 155 69 30.8 1.21 (0.82-1.80) 
  
High 229 78 25.4 0.69 (0.41-1.15) 
  
Mother looks 
after cattle 
No 598 255 29.9 1   
<0.001 
1  
 <0.001 
Yes 44 12 21.4 0.64 (0.58-0.70)  0.54  (0.45-0.64) 
Nutritional 
status (mid-
upper arm 
circumference 
in cm
d
) 
<23.9 81 41 33.6 1.19 (0.57-2.56) 
0.0042 
1.05 (0.39-2.83) 
<0.001 
24-25.9 181 77 29.8 1   1 
 
26-27.9 130 48 27.0 0.87 (0.56-1.35) 0.73 (0.42-1.28) 
>28 219 85 28.0 0.91 (0.57-1.46)  0.79  (0.42-1.49) 
HIV infection 
No 608 251 29.2 1   
 <0.001 
1   
 <0.001 Yes, no CTX
e 13 7 35.0 1.30 (1.21-1.40) 1.46 (1.11-1.92) 
Yes, on CTXe 2 3 60.0 3.63 (1.58-8.34) 4.30 (0.59-31.3) 
a 
95% confidence intervals are given, based on robust standard errors to account for intracluster correlation within 
recruitment sites  
b
 p values
 
are derived from the Wald test  
c 
Mijikenda are the indigenous coastal population 
d
 For continuous variables we tested for associations prior to categorisation and inclusion in the model. Where there was 
non-linearity, natural cubic splines were used (Supplementary Figure 2). Data were categorised for ease of presentation, and 
the largest group was used as the reference group. 
e
CTX=co-trimoxazole prophylaxis 
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Figure 1: Study design and recruitment of participants by study site 
a, Recruitment timeline and sub-studies undertaken at each study site. b, 
Recruitment of mothers in the cohort study. *The denominator for live-births in the 
prospective cohort period, used to calculate incidence of early onset disease in Kilifi 
County Hospital (KCH) excluded those who did not deliver, or had a stillbirth (leaving 
6598.**These mothers (7967) were included in the analysis of risk factors for 
maternal GBS colonisation. §These births (7833) were included in analyses 
assessing GBS as a risk factor for stillbirth or perinatal death. §§These live-births 
(7408) were included in analyses assessing GBS as a risk factor for preterm birth, 
low birth-weight or possible serious bacterial infection. c Recruitment for the vertical 
transmission study (maternal-neonatal dyads), a subset of mothers who delivered in 
KCH. d Recruitment for stillbirth nested case-control study including mothers who 
delivered in KCH and had a stillbirth, and controls. 
Figure 2: Interaction of risk factors at delivery with maternal GBS colonisation 
associated with adverse newborn outcomes. 
Interactions between maternal risk factors at delivery (maternal fever, maternal 
urinary tract infection, prolonged rupture of membranes) and adverse perinatal 
outcomes (very preterm birth, very low birth weight, stillbirth, possible serious 
bacterial infection), in the presence and absence of maternal GBS colonisation. 
Odds ratios are given for maternal exposures and associated perinatal outcome 
(listed vertically) with 95% confidence intervals illustrated with error bars for the odds 
ratio in each case. Interactions were included in multivariable models if there was 
evidence of interaction at the p<0.1 level in univariable analyses. P values given 
here are for interaction tests in imputed multivariable models (details for all models in 
Supplementary tables 5-9). **Possible serious bacterial infection (pSBI) is defined in 
Supplementary table 1; it is a clinical diagnosis used to guide empiric treatment of 
neonates for possible serious bacterial infections in resource-poor settings. 
 
Figure 3: GBS types colonising mothers and causing disease.  
a, Invasive neonatal GBS disease cases decrease after the first few days of birth in 
Kilifi County Hospital neonatal admissions (1998-2013), and serotype III causes an 
increasing proportion of disease; b: The clinical infection syndrome is predominantly 
sepsis in the first few days after birth in neonates admitted with invasive GBS 
disease to Kilifi County Hospital (1998-2013) with increasing numbers of neonates 
admitted with meningitis with or without sepsis later in the neonatal period; c, The 
percentage of different serotypes in GBS isolates from maternal colonisation, early 
onset disease (EOD) and late onset disease (LOD) in neonates shows a stepwise 
increase in serotype III from maternal colonisation to EOD and LOD; d, The 
percentage of different clonal complexes in GBS isolates from maternal colonisation, 
neonatal sepsis and neonatal meningitis (+/- sepsis) shows the increasing 
dominance of CC-17 in neonatal disease, particularly in neonatal meningitis. 
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 Figure 4: Phylogenetic reconstructions of GBS isolates  
Maximum likelihood phylogenies, with recombinant regions removed, are shown 
separately for each clonal complex. Background shading indicates ST-17 isolates 
within CC-17. Serotypes are illustrated for each clonal complex in the innermost 
circle. The next circle describes the sample source of the GBS isolate (neonatal 
invasive, or maternal colonising (by site of recruitment)). For maternal colonising 
isolates, epidemiological details are illustrated. From the outermost circle, these are: 
maternal HIV status (negative, HIV-infected, HIV infected and taking prophylactic co-
trimoxazole), socio-economic status (high, medium, low and very low), ethnicity 
(Mijikenda or non-Mijikenda) and the presence or absence of cattle contact.  
Surveillance of neonatal invasive bacterial disease 
Maternal cohort study 
Stillbirth nested case-control study 
Vertical transmission study 
Maternal cohort study 
Maternal cohort study 
01.04.2012 
01.07.2012 
01.08.2011 
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31.07.2013 
a 
b 
c 
d 
Key 
Urban  
Coast Provincial General Hospital (CPGH 
Rural  
Bamba and Ganze 
Semi-rural 
Kilifi County Hospital (KCH) 
01.05.2012 
 Outcome: Very preterm birth 
Exposure: Maternal fever 
 
 
 
 
Outcome: Very low birth weight 
Exposure: Maternal fever 
 
 
 
Outcome: Stillbirth  
Exposure: Maternal urinary tract 
infection 
 
 
Outcome: Possible Serious 
Bacterial infection**  
Exposure: Prolonged rupture of 
membranes 
{ 
 { 
 { 
 { 
 
GBS positive 
GBS negative 
OR (presence vs absence of exposure) 
0.1 1 10 100
P=0.019 
P<0.001 
P=0.104 
P=0.104 
a 
b 
c 
Percentage of GBS Clonal Complexes 
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